Using guadecitabine to enhance immune response against prostate cancer
Guadecitabine-directed immune regulation in targeting prostate cancer
['FUNDING_R21'] · UNIVERSITY OF LOUISVILLE · NIH-11111889
This study is looking at how a new treatment called guadecitabine can help the immune system better spot and fight prostate cancer cells, which could lead to better options for patients who haven't had much success with current therapies.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF LOUISVILLE (nih funded) |
| Locations | 1 site (LOUISVILLE, UNITED STATES) |
| Trial ID | NIH-11111889 on ClinicalTrials.gov |
What this research studies
This research investigates how guadecitabine, a hypomethylating agent, can improve the immune system's ability to recognize and attack prostate cancer cells. By reversing certain epigenetic changes, the study aims to enhance the presentation of cancer antigens, making the cancer cells more visible to immune cells like CD8+ T cells. The approach focuses on modifying the tumor microenvironment to increase immune cell infiltration and improve treatment outcomes for patients with prostate cancer. If successful, this could lead to more effective immunotherapy options for patients who currently have limited responses to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer, particularly those who have not responded well to traditional immunotherapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone any form of immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new immunotherapy strategy that significantly improves treatment outcomes for prostate cancer patients.
How similar studies have performed: Other research has shown promise in using epigenetic therapies to enhance immune responses in various cancers, suggesting that this approach may be viable for prostate cancer as well.
Where this research is happening
LOUISVILLE, UNITED STATES
- UNIVERSITY OF LOUISVILLE — LOUISVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARAN, DEV — UNIVERSITY OF LOUISVILLE
- Study coordinator: KARAN, DEV
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer